Bristol Myers Squibb said its multiple myeloma therapy Zenbexus, recently granted FDA accelerated approval, reduced the risk of disease progression by 51% versus standard therapy in a Phase 3 trial. The update positions Zenbexus as a potential next-line option for patients where disease control is time-critical. Accelerated approvals typically rely on surrogate endpoints; the Phase 3 result described in the update adds confirmatory strength for effectiveness claims. Market participants will watch conversion plans, durability of benefit, and how the regimen compares with existing multiple myeloma standards across patient subgroups.